First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.

First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients. is a phase 3, randomised interventional study registered as NCT06840782 by Gustave Roussy, Cancer Campus, Grand Paris, with a registry enrolment figure of 124 participants, started 2025-09-09 and due to reach its primary completion in 2030-02. Interventions recorded: Radical local treatment; SoC-based immunotherapy (+/- chemotherapy). Conditions listed: Oligometastatic Non-small Cell Lung Cancer (NSCLC). Primary outcome: Overall Survival (OS).. Lung eligibility wording from the registry: "* Histologically proven advanced synchronous oligometastatic stage IV NSCLC". Sites: France. No results are recorded here; the registry entry is the source.